$CSBTF

Kuros Biosciences AG reported mixed Q4 2025 earnings, with a notable increase in revenue from its spinal fusion products. However, the company also reported higher than expected R&D expenditures, which impacted profitability. Analysts expressed concerns regarding the long-term sustainability of growth given the high costs. The management emphasized their commitment to developing innovative regenerative medicine solutions. Overall, market sentiment appears cautious but optimistic about potential breakthroughs.